Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03157167 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
A Phase 1 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03157167 is a Phase 1 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT03157167, a Phase 1 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept in the same subjects.
Interventions
- DRUG Tc99m-tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03157167
The ClinicalTrials.gov registry entry for NCT03157167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc99m-tilmanocept is the first listed.
NCT03157167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03157167 about?
NCT03157167 is a clinical study titled "An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)". To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept in the same subjects.
What is the current status of trial NCT03157167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-12-01. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT03157167?
The interventions under investigation include: Tc99m-tilmanocept (DRUG).
Who is sponsoring clinical trial NCT03157167?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.